fda counsel.com 1 the medical device user fee and modernization act of 2002 -- “mdufma” overview...
DESCRIPTION
FDACounsel.com 3 User Fees Title I of MDUFMA = User Fees Adds new §§ 737, 738, et seq., of Federal Food, Drug, and Cosmetic Act On or after 10/1/02, types of submissions triggering full fees for the submitter: PMA “Premarket Report” – i.e., a report under 515(c)TRANSCRIPT
FDACounsel.com 1
The Medical Device User Fee and Modernization
Act of 2002 -- “MDUFMA”
Overview of Key Provisions
Michael A. Swit, Esq.Law Offices of Michael A. Swit
FDACounsel.com 2
Background Two bills in Congress – both
introduced by James Greenwood (R-Pa.) H.R. 3580 – “Medical Device
Amendments of 2001” H.R. 5651 – “MDUFMA” Signed by President on 10/26/02 Public Law 107-250
FDACounsel.com 3
User Fees Title I of MDUFMA = User Fees Adds new §§ 737, 738, et seq., of
Federal Food, Drug, and Cosmetic Act On or after 10/1/02, types of
submissions triggering full fees for the submitter: PMA “Premarket Report” – i.e., a report
under 515(c)
FDACounsel.com 4
User Fees … Submissions Triggering Full User
Fees: “Panel Track Supplement” – i.e., one
that requests: either:
a significant change in design or performance of device,
or a new indication for use; and for which clinical data are generally necessary to
provide a reasonable assurance of safety and effectiveness
FDACounsel.com 5
User Fees … Submissions Triggering Full
User Fees: “Efficacy Supplement”
Definition: a supplement to an approved premarket application under section 351 of the Public Health Service Act that requires substantive clinical data
FDACounsel.com 6
User Fees … “Partial Fees” – types of
submissions: “180-day Supplement” –
Definition -- § 738 – one that requests a significant change in components, materials, design, specification, software, color additives, or labelingBUTIs not a panel-track supplement
Fee amount – 21.5% of fee for a full PMA – or $33,110
FDACounsel.com 7
User Fees … “Partial Fees” – types of
submissions: “Real-Time Supplement”
Definition – a supplement requesting a minor change to the device such as to the design of the device, software, manufacturing, sterilization or labelingandWhere applicant has requested – and FDA granted – a meeting or similar forum to jointly review the status of the supplement
Fee amount – 7.2% of PMA fee -- $11,088
FDACounsel.com 8
User Fees … 510(k)s – 1.42% of PMA fee or
$2,186.80 Exempt Submissions – no
fees!! “Humanitarian Use Devices” – Biologic devices where the application
seeks to get a license providing “for further manufacturing use only”
FDACounsel.com 9
User Fees … Exempt Submissions – no fees!!
… Filings by state, local or federal
governmental bodies. 510(k)’s submitted for third-party
review pediatric use only filings – must be
“solely” for pediatric labeling later “adult” filings – must pay
appropriate fee
FDACounsel.com 10
User Fees … Logistics
Payment -- due on submission (if you filed between 10/1 and 10/26, you will be billed
Amounts – set by HHS going forward, except for FY 2003, where Congress set the PMA user fees as $154,000
FDACounsel.com 11
User Fees … Logistics …
Refunds – “refused for filing” – get back 75% application withdrawn before “filing decision” –
get back 75% application withdrawn before first FDA action –
FDA “may return some or all of fee” based on “level of effort” FDA already expended
must request within 180 days of original fee due date
FDACounsel.com 12
User Fees … Small businesses – may be entitled to
a waiver or reduction in fees definition -- < $30 MM in sales amount of reduction –
PMA -- 38% of normal fee (= $58,520) 510(k) – 80% of normal fee (= $1,749) – but, does
not apply in FY 2003 Note – FDA, in 11/21/02 FR notice, includes
affiliate sales in calculating $30 mm “small” cutoff – is consistent with MDUFMA
Need to file certified tax returns to qualify
FDACounsel.com 13
User Fees … Targets for FY Gross Fee
Revenues 2003 -- $25,125,000 2004 -- $27,255,000 2005 -- $29,785,000 2006 -- $32,615,000 2007 -- $35,000,000
FDACounsel.com 14
User Fees … What if you don’t submit?
Application will be considered incomplete and shall not be accepted for filing
Other Requirements Under MDUFMA Title I: §103 – Annual reports to Congress on FDA
progress toward meeting performance goals in the “letters”
FDACounsel.com 15
User Fees … Other Title I Requirements …
§104 – additional appropriations for post-market surveillance –
2003 – an increase of $3 MM 2004 – an increase of $6 MM Study on various aspects of FDA’s ability to
conduct postmarket surveillance Study Report – Due Jan. 10, 2007
FDACounsel.com 16
User Fees … Other Title I Requirements …
§105 – “Consultation” – relative to reauthorization after FY 2007, the Secretary is to consult with:
House Energy & Commerce Cmte. Senate Health, Ed., Labor & Pensions Cmte “scientific and academic experts, health care
professionals, reps of patient and consumer advocacy groups” and
regulated industry
FDACounsel.com 17
User Fees … Other Title I Requirements …
§106 – Effective Date – 10-26-02, but applies to filings made between 10-1 and 10-26
§107 – Sunset – midnight on September 30, 2007.
§738(g) – “Early Sunset” aka “Eclipse” provisions – complicated formula; if FDA doesn’t meet goals, early sunset after FY 2005
FDACounsel.com 18
User Fees … FDA Implementation – 11/21/02
Federal Register – 67 Fed. Reg. 70228 lays out fees FDA can’t collect until there are
“enabling appropriations” Interim procedures:
FDACounsel.com 19
Title II – Selected Key Amendments on Medical Devices
§204 – “Combination Products” -- Amends §503(g) of the Act to: Establish, at the Commissioner’s office
level, an office on Combination Products Office duties:
to promptly assign FDA “Center” with “primary jurisdiction” to the product
note: “primary jurisdiction” not changed coordinate reviews among centers ensure consistency among similar reviews Annual report to Congress on implementation
FDACounsel.com 20
Title II – Amendments re Regulation of Medical Devices … §205 – “Report on Certain
Devices” – by 10/26/03, Secretary to report to Congress on “the timeliness and effectiveness of device premarket reviews by centers other than [CDRH]…” detailed logs recommendations on how to improve
FDACounsel.com 21
Title II – Amendments re Regulation of Medical Devices … §209 – “Modular Review” – amends
§515(c) of Act to formalize the modular review process. Note – is a permanent change to
FFDCA; however, is not applicable if fees are not being collected due to either:
Eclipse under §738(g); or Full sunset after FY 2007 (i.e., no
reauthorization)
FDACounsel.com 22
Title II – Amendments re Regulation of Medical Devices … §210 – Pediatric Expertise Regarding
Classification-Panel Review of Premarket Applications – amends §515(c) of FFDCA to require that, “where appropriate”, panels include or consult with “pediatric experts.”
§212 – IOM Study on Postmarket Surveillance re Pediatric Populations – study to see if system “provides adequate safeguards” on device use in pediatric populations. will include focus on implanted devices Congressional report of study due in 4 years
FDACounsel.com 23
Title II – Amendments re Regulation of Medical Devices … §213 – Guidance on Pediatric Devices –
within 270 days of enactment, Secretary “shall issue” guidance on: type of information necessary to provide
reasonable assurance of the safety and effectiveness of medical devices intended for pediatric use; and
protections of pediatric subjects in clinical investigations of the safety or effectiveness of such device.
FDACounsel.com 24
Questions?Call, e-mail, fax or write:
Michael A. Swit, Esq.Law Offices of Michael A. Swit
539 Samuel Ct., Suite 229Encinitas, California 92024
760-815-4762 ♦ 760-454-2979 (fax)[email protected]
http://www.fdacounsel.com
FDACounsel.com 25
About the speaker ...
Michael A. Swit has extensive experience in all aspects of FDA regulation with a particular emphasis on drugs and medical device regulation. In addition to his regulatory law experience, Mr. Swit also served for three and a half years as vice president and general counsel of Pharmaceutical Resources, Inc. (PRI) a prominent generic drug company and, thus, brings an industry and commercial perspective to his representation of FDA-regulated companies. While at PRI from 1990 to late 1993, Mr. Swit spearheaded the company’s defense of multiple grand jury investigations, other federal and state proceedings, and securities litigation stemming from the acts of prior management. Mr. Swit then served from 1994 to 1998 as CEO of Washington Business Information, Inc. (WBII) a premier publisher of FDA regulatory newsletters and other specialty information products for the FDA publishing company. Before starting FDACounsel.com, he was with Heller Ehrman from May 2001 to May 2003, and also twice in private practice with McKenna & Cuneo, from 1988 to 1990 and, most recently, from 1999 to 2001, first in that firm’s D.C. office and most recently, in its San Diego office. He first practiced FDA regulatory law with the D.C. office of Burditt & Radzius from 1984 to 1988. Mr. Swit has taught and written on a wide variety of subjects relating to FDA law including, since 1989, co-directing a three-day intensive course on the generic drug approval process, serving on the Editorial Board of the Food & Drug Law Journal, and editing a guide to the generic drug approval process, Getting Your Generic Drug Approved, published by WBII. Mr. Swit holds an A.B., magna cum laude, with high honors in history, in 1979, from Bowdoin College, and earned his law degree from Emory University in 1982. He is a member of the California, Virginia and District of Columbia bars.
FDACounsel.com